Inpatient Versus Outpatient Administration of Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia

被引：0
|
作者：
Sanka, Pranavi [1 ]
Egan, Pamela [2 ]
Niroula, Rabin [2 ]
Yakirevich, Inna [3 ]
Gardner, David [3 ]
Reagan, John L. [4 ]
机构：
[1] Brown Univ, Lifespan, Alpert Med Sch, Providence, RI 02912 USA
[2] Brown Univ, Lifespan Canc Inst, Legoretta Canc Ctr, Providence, RI 02912 USA
[3] Lifespan Canc Inst, Providence, RI USA
[4] Brown Univ, Legorreta Canc Ctr, Providence, RI 02912 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-184948
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia
    DiNardo, Courtney D.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 82 - 83
  • [2] Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
    Saliba, Antoine N.
    John, August J.
    Kaufmann, Scott H.
    CANCER DRUG RESISTANCE, 2021, 4 (01) : 125 - 142
  • [3] Tumor Lysis Syndrome Risk in Outpatient Versus Inpatient Administration of Venetoclax and Hypomethlators for Acute Myeloid Leukemia
    Pelcovits, Aryeh
    Bakow, Brianna
    Waroich, Jozal
    Egan, Pamela C.
    Niroula, Rabin
    Olszewski, Adam J.
    Reagan, John L.
    BLOOD, 2020, 136
  • [4] Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia
    Ari Pelcovits
    Jozal Moore
    Brianna Bakow
    Rabin Niroula
    Pamela Egan
    John L. Reagan
    Supportive Care in Cancer, 2021, 29 : 5323 - 5327
  • [5] Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia
    Pelcovits, Ari
    Moore, Jozal
    Bakow, Brianna
    Niroula, Rabin
    Egan, Pamela
    Reagan, John L.
    SUPPORTIVE CARE IN CANCER, 2021, 29 (09) : 5323 - 5327
  • [6] Inpatient versus outpatient hypomethylating agent induction for acute myeloid leukemia as a predictor for survival
    Jeurkar, Chetan
    Wilde, Lindsay
    Leiby, Benjamin E.
    Banks, Joshua
    Kasner, Margaret
    Keiffer, Gina
    Filicko-O'Hara, Joanne
    Palmisiano, Neil
    LEUKEMIA RESEARCH, 2021, 103
  • [7] The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement
    Otoukesh, Salman
    Zhang, Jianying
    Nakamura, Ryotaro
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    Aldoss, Ibrahim
    LEUKEMIA & LYMPHOMA, 2020, 61 (08) : 2020 - 2023
  • [8] Efficacy of hypomethylating agents and Venetoclax in unfit patients with acute myeloid leukemia
    Rieger, M.
    Manz, M. G.
    Muller, R.
    Theocharides, A. P. A.
    Schwotzer, R.
    SWISS MEDICAL WEEKLY, 2020, : 17S - 17S
  • [9] The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study
    Xin, Fei
    Yu, Yan-Hui
    Shen, Xu-Liang
    Zhang, Guo-Xiang
    HEMATOLOGY, 2024, 29 (01)
  • [10] Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting
    Nanni, Jacopo
    Papayannidis, Cristina
    Cristiano, Gianluca
    Marconi, Giovanni
    Sartor, Chiara
    Parisi, Sarah
    Ottaviani, Emanuela
    Baldini, Lorenza
    Testoni, Nicoletta
    Baldazzi, Carmen
    Ricci, Paolo
    Bezzi, Chiara Di Giovanni
    Abd-alatif, Rania
    Paolini, Stefania
    Cavo, Michele
    Curti, Antonio
    BLOOD, 2020, 136
12345